TriSalus Life Sciences' (TLSI) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• TriSalus Life Sciences has received a "sell (D-)" rating from Weiss Ratings, signaling continued concern among analysts about the company’s financial performance.
• Despite a majority of analysts rating the stock as a "Buy," recent reports have led to a downgrade from "hold" to "sell" by Wall Street Zen, adding to the mixed outlook for the stock.
• TriSalus Life Sciences reported a loss per share of ($0.27), which missed consensus estimates, though its revenue for the quarter exceeded expectations at $11.21 million.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities researchers at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen cut shares of TriSalus Life Sciences from a "hold" rating to a "sell" rating in a report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $10.90.

TriSalus Life Sciences Price Performance

Shares of TLSI traded up $0.07 during mid-day trading on Wednesday, reaching $4.85. The stock had a trading volume of 189,127 shares, compared to its average volume of 126,082. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $5.88. The business's fifty day moving average is $4.65 and its 200 day moving average is $5.05. The firm has a market cap of $241.87 million, a price-to-earnings ratio of -4.11 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). The business had revenue of $11.21 million for the quarter, compared to the consensus estimate of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $29,000. JPMorgan Chase & Co. increased its position in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock worth $41,000 after purchasing an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $47,000. Charles Schwab Investment Management Inc. acquired a new stake in TriSalus Life Sciences during the 1st quarter worth approximately $55,000. Finally, New York State Common Retirement Fund acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $108,000. Institutional investors and hedge funds own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.